Vitamin B2 Shows Promise in New Cancer Therapies

A deficiency in vitamin B2, also known as riboflavin, may increase the susceptibility of tumor cells to a specific type of cell death called ferroptosis, according to recent research from the Rudolf Virchow Centre at the University of Würzburg in Germany. This discovery opens potential new avenues for cancer treatment by targeting the metabolic pathways of this essential vitamin.

The Role of Vitamin B2 in Cancer Cell Protection

Vitamin B2 is a vital nutrient that the human body cannot produce on its own, requiring intake through diet from sources like dairy products, eggs, meat, and green vegetables. It plays a crucial role in converting food into energy and protecting cells from oxidative damage. However, researchers have found that this protective function also extends to cancer cells, shielding them from ferroptosis.

“Vitamin B2 plays a crucial role in protecting cancer cells from ferroptosis, a special form of programmed cell death,” explains Vera Skafar, a PhD student at the Rudolf Virchow Centre and member of the research group led by Professor José Pedro Friedmann Angeli. The findings were published in Nature Cell Biology.

Understanding Ferroptosis

Ferroptosis is a form of regulated cell death distinct from other pathways. It’s triggered when iron-driven lipid peroxidation overwhelms a cell’s antioxidant defenses. Cancer cells frequently evade ferroptosis by strengthening their redox defense systems. The University of Würzburg research highlights vitamin B2 metabolism as a key contributor to these defenses, suggesting that disrupting riboflavin-derived cofactors could weaken this resistance and make tumors more vulnerable.

FSP1 and the Antioxidant Recycling Pathway

The protein FSP1 is critical for protecting healthy cells from cell death, and vitamin B2 supports its function. Researchers used genome editing and cancer cell models to demonstrate that a vitamin B2 deficiency increased the susceptibility of cancer cells to ferroptosis. This suggests that inhibiting vitamin B2 metabolism could selectively trigger the death of cancer cells.

Roseoflavin as a Potential Inhibitor

To explore this therapeutic potential, the research team investigated roseoflavin, a natural compound structurally similar to vitamin B2 produced by bacteria. Laboratory tests on cancer cell models showed that roseoflavin induced ferroptosis at low concentrations, demonstrating the feasibility of this approach. Professor Friedmann Angeli noted the promising results.

Future Directions and Broader Implications

The Rudolf Virchow Centre team is now focused on developing more effective inhibitors of vitamin B2 metabolism for evaluation in preclinical cancer models. Beyond cancer, ferroptosis is increasingly recognized as a factor in neurodegenerative diseases, organ transplantation, and ischemia-reperfusion injury. Understanding how vitamin B2 metabolism influences ferroptosis could therefore have wider implications for treating a range of conditions.

The study received funding from the German Research Foundation (DFG) through the priority programme “Ferroptosis: from Molecular Basics to Clinical applications” (SPP2306) and the DeciFerr project, supported by the European Research Council (ERC) with a Consolidator Grant of almost two million euros. University of Würzburg News